BRB-002 was safe at all doses tested, with no SAEs reportedPhase 2 proof-of-concept study in patients with established atherosclerosis is expected to initiate in 1H 2025 PALO ALTO, Calif. and NEEDHAM, ...
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company’s ...
Concussions and repetitive head trauma in sports like football and boxing, once accepted as an unpleasant consequence of intense athletic competition ...